当院のご案内

  1. 石川眼科医院 ホーム
  2. 当院のご案内
  3. 論文紹介

論文紹介

院長 石川 浩平

医学博士　日本眼科学会認定専門医
光線力学的療法認定医　麻酔科標榜医

論文業績集

  1. Sawa M, Iwata E, Ishikawa K, Gomi F, Nishida K, Terasaki H. Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular degeneration. Jpn J Ophthalmol. 2012 Sep;56(5):470-5.
  2. Iwata E, Ueno S, Ishikawa K, Ito Y, Uetani R, Piao CH, Kondo M, Terasaki H. Focal macular electroretinograms after intravitreal injections of bevacizumab for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012 Jun 28;53(7):4185-90.
  3. Uetani R, Ito Y, Oiwa K, Ishikawa K, Terasaki H. Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy. Eye (Lond). 2012 May;26(5):640-9.
  4. Nishiguchi KM, Yasuma TR, Tomida D, Nakamura M, Ishikawa K, Kikuchi M, Ohmi Y, Niwa T, Hamajima N, Furukawa K, Terasaki H. C9-R95X polymorphism in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012 Jan 31;53(1):508-12.
  5. Takeuchi K, Kachi S, Iwata E, Ishikawa K, Terasaki H. Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration. Eye (Lond). 2012 Jan;26(1):51-60.
  6. Takahashi A, Ito Y, Iguchi Y, Yasuma TR, Ishikawa K, Terasaki H. Axial length increases and related changes in highly myopic normal eyes with myopic complications in fellow eyes. Retina. 2012 Jan;32(1):127-33.
  7. Tanabe H, Ito Y, Iguchi Y, Ozawa S, Ishikawa K, Terasaki H. Correlation between cross-sectional shape of choroidal veins and choroidal thickness. Jpn J Ophthalmol. 2011 Nov;55(6):614-9.
  8. Ishikawa K, Nishihara H, Ozawa S, Piao CH, Ito Y, Kondo M, Terasaki H. Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):273-80.
  9. Hatta Y, Ishikawa K, Nishihara H, Ozawa S, Ito Y, Terasaki H. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography. Retina. 2010 Mar;30(3):495-502.
  10. Ozawa S, Ishikawa K, Ito Y, Nishihara H, Yamakoshi T, Hatta Y, Terasaki H. Differences in macular morphology between polypoidal choroidal vasculopathy and exudative age-related macular degeneration detected by optical coherence tomography. Retina. 2009 Jun;29(6):793-802.
  11. Kachi S, Ishikawa K, Terasaki H. [New therapies for age-related macular degeneration] Nippon Ganka Gakkai Zasshi. 2009 Apr;113(4):479-91.
  12. Yamakoshi T, Kachi S, Sugita J, Asami T, Ishikawa K, Ito Y, Terasaki H. Triamcinolone-assisted removal of internal limiting membrane enhances the effect of vitrectomy for diabetic macular edema. Ophthalmic Res. 2009;41(4):203-9. Epub 2009 May 15.
  13. Ishikawa K, Nishihara H, Ozawa S, Piao CH, Ito Y, Kondo M, Terasaki H. Focal macular electroretinograms after photodynamic therapy combined with posterior juxtascleral triamcinolone acetonide. Retina. 2009 Jun;29(6):803-10.
  14. Ishikawa K, Ito Y, Mizutani R, Kikuchi M, Nishihara H, Terasaki H. New algorithm to analyze optical coherence tomographic images quantitatively. Jpn J Ophthalmol. 2008 May-Jun;52(3):182-9.
  15. Nishihara H, Kondo M, Ishikawa K, Sugita T, Piao CH, Nakamura Y, Terasaki H. Focal macular electroretinograms in eyes with wet-type age-related macular degeneration.Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3121-5.
  16. Kikuchi M, Hishida A, Ishikawa K, Sagawa H, Suzuki K, Ito Y, Terasaki H, Hamajima N. Associations between serum C-reactive protein (CRP) levels and polymorphisms of CRP, interleukin 1B, and tumor necrosis factor genes among Japanese health checkup examinees. Asian Pac J Cancer Prev. 2007 Jan-Mar;8(1):87-92.
  17. Ishikawa K, Kondo M, Ito Y, Kikuchi M, Nishihara H, Piao CH, Sugita T, Terasaki H. Correlation between focal macular electroretinograms and angiographic findings after photodynamic therapy. Invest Ophthalmol Vis Sci. 2007 May;48(5):2254-9.
  18. Kikuchi M, Nakamura M, Ishikawa K, Suzuki T, Nishihara H, Yamakoshi T, Nishio K, Taki K, Niwa T, Hamajima N, Terasaki H. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology. 2007 Sep;114(9):1722-7.
  19. Iguchi Y, Ito Y, Kikuchi M, Ishikawa K, Oshima H, Yatsuya H, Terasaki H. Seasonal variations of acute massive submacular haemorrhage associated with age-related macular degeneration. Br J Ophthalmol. 2006 Oct;90(10):1256-8.
  20. Kondo M, Ito Y, Miyata K, Kondo N, Ishikawa K, Terasaki H. Effect of axial length on laser spot size during photodynamic therapy: an experimental study in monkeys. Am J Ophthalmol. 2006 Jan;141(1):214-5.
  21. Kobayashi C, Kagami H, Kito K, Ishikawa K, Ebisawa K, Ueda M, Terasaki H. Selective and efficient culturing of retinal pigment epithelial cells using a feeder layer. Cytotherapy. 2005;7(5):427-37.
  22. Ishikawa K, Terasaki H, Mori M, Sugita K, Miyake Y. Optical coherence tomography before and after vitrectomy with internal limiting membrane removal in a child with optic disc pit maculopathy. Jpn J Ophthalmol. 2005 Sep-Oct;49(5):411-3.
  23. Yamada M, Ishikawa K, Terasaki H. Vitreomacular traction after macular translocation surgery in a highly myopic eye. Retina. 2005 Feb-Mar;25(2):221-3.
  24. Ishikawa K, Terasaki H, Kobayashi C, Niwa Y, Piao CH, Ito Y, Kondo M, Miyake Y. Changes in foveal thickness and macular function after transpupillary thermotherapy for age-related macular degeneration. Ophthalmic Res. 2005 Jan-Feb;37(1):34-42.
  25. Terasaki H, Ishikawa K, Niwa Y, Piao CH, Niwa T, Kondo M, Ito Y, Miyake Y. Changes in focal macular ERGs after macular translocation surgery with 360 degrees retinotomy. Invest Ophthalmol Vis Sci. 2004 Feb;45(2):567-73.
  26. Terasaki H, Ishikawa K, Suzuki T, Nakamura M, Miyake K, Miyake Y. Morphologic and angiographic assessment of the macula after macular translocation surgery with 360 degrees retinotomy. Ophthalmology. 2003 Dec;110(12):2403-8.
  27. Ito Y, Terasaki H, Suzuki T, Kojima T, Mori M, Ishikawa K, Miyake Y. Mapping posterior vitreous detachment by optical coherence tomography in eyes with idiopathic macular hole. Am J Ophthalmol. 2003 Mar;135(3):351-5.

このページのトップへ

主要論文の要約

  1. Ishikawa K, Kondo M, Ito Y, Kikuchi M, Nishihara H, Piao CH, Sugita T, Terasaki H. Correlation between focal macular electroretinograms and angiographic findings after photodynamic therapy. Invest Ophthalmol Vis Sci. 2007 May;48(5):2254-9.

    これまでに名古屋大学では、多くの黄斑部に対する治療の評価を、モニターによる眼底直視下で局所的な網膜電図を得る黄斑部局所網膜電図を用いて行ってきました。本研究は今現在も加齢黄斑変性治療の重要な位置を占める、光線力学的療法前後の黄斑部網膜機能の評価を黄斑部局所網膜電図を用いて行ったものです。我々は光線力学的療法の1週間後に一過性の黄斑機能の悪化がみられ、3か月後までに徐々に改善していき、レーザーの照射範囲に一致した脈絡膜循環障害が強い症例は黄斑部網膜機能の障害も強いことを見いだしました。

  2. Ishikawa K, Nishihara H, Ozawa S, Piao CH, Ito Y, Kondo M, Terasaki H. Focal macular electroretinograms after photodynamic therapy combined with posterior juxtascleral triamcinolone acetonide. Retina. 2009 Jun;29(6):803-10.

    次に我々はステロイドの抗炎症作用により、光線力学的療法の悪影響を抑えることができるかを、トリアムシノロンを光線力学的療法の1週間前にテノン嚢下注射した症例を対象に、黄斑部局所網膜電図の検討を行いました。その結果は、期待通り、単独の光線力学的療法でみられた、光線力学的療法1週間後の黄斑部網膜機能の悪化はなくなり、光線力学的療法3か月後まで治療前の黄斑部網膜機能が維持されました。しかし、単独の光線力学的療法同様、レーザーの照射範囲に一致した脈絡膜循環障害が強い症例は黄斑部網膜機能の障害が強かったことがわかりました。

  3. Ishikawa K, Nishihara H, Ozawa S, Piao CH, Ito Y, Kondo M, Terasaki H. Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):273-80.

    さらに我々は抗血管内皮増殖因子（VEGF）抗体であるベバシズマブ（アバスチン®）を光線力学的療法の1週間前に硝子体注射した症例を対象とし、黄斑部局所網膜電図の検討を行いました。トリアムシノロン併用光線力学的療法同様、光線力学的療法1週間後の黄斑部網膜機能の悪化は抑えられ、さらに光線力学的療法の3か月後には黄斑部網膜機能の改善もみられました。本研究では光線力学的療法のレーザー照射範囲に一致した脈絡膜循環障害が強い症例でも黄斑部網膜機能の障害はなく、光線力学的療法により脈絡膜循環障害は生じるが、その後発生する血管内皮増殖因子（VEGF）を抑えることにより、光線力学的療法直後の滲出の増加を抑制し、黄斑部網膜機能の低下も抑制したと考えられました。

このページのトップへ